{
  "docId": "019de076-87a3-715f-b988-6da9cfb3fd56",
  "docSlug": "560176b410a72a6b2e67af5dd2a20758",
  "documentTitle": "NeuroSense Therapeutics | Investor Presentation Deck | 33 slides",
  "authorId": "neurosense-therapeutics",
  "authorName": "NeuroSense Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 33,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "appendix_methodology",
  "function": "other",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-87a3-715f-b988-6da9cfb3fd56/14",
  "deckHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56",
  "deckJsonHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56.json",
  "deckAnchorHref": "/decks/019de076-87a3-715f-b988-6da9cfb3fd56#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.24
      },
      "kind": "list",
      "text": "Exclusion Criteria: Patients with known hypersensitivity to celecoxib or ciprofloxacin and related exclusions derivative from the celecoxib and ciprofloxacin labels",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b3e917e-3053-48e0-a1ce-99c85845fb42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.07,
        "y": 0.24
      },
      "kind": "list",
      "text": "Inclusion Criteria: Males or females 18-75, ALS diagnosis, <30 months duration, ALSFRS-R slope >= 0.3, ALSFRS-R >= 25, Swallowing >= 3, concurrent Riluzole/Edaravone/TUDCA allowed, SVC >= 60%, 18 < BMI < 30",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7c74f51-7467-4cd8-a1f5-9f2239b71be4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "PrimeC Phase 2b Study Inclusions / Exclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "963fe80b-9535-4adf-b116-a5e10e0f3148",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 6,
      "beatId": "34d973c9-414c-4e7d-9b2b-216172775550",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents PrimeC as a solution, highlighting its unique formulation, preclinical efficacy, and promising clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}